|
GTF2H3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.404699999767E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.19569999999614E-05 |
| Normal-vs-Stage2 |
1.164520E-03 |
| Normal-vs-Stage3 |
1.5821999999055E-07 |
| Normal-vs-Stage4 |
1.29749999999706E-06 |
| Stage1-vs-Stage2 |
8.659200E-01 |
| Stage1-vs-Stage3 |
2.195000E-01 |
| Stage1-vs-Stage4 |
1.942600E-01 |
| Stage2-vs-Stage3 |
2.944400E-01 |
| Stage2-vs-Stage4 |
2.821000E-01 |
| Stage3-vs-Stage4 |
8.519600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.31380000004222E-06 |
| Normal-vs-AfricanAmerican |
4.581800E-02 |
| Normal-vs-Asian |
3.83670000000391E-05 |
| Caucasian-vs-AfricanAmerican |
2.605000E-01 |
| Caucasian-vs-Asian |
6.180800E-01 |
| AfricanAmerican-vs-Asian |
1.663950E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.93609997320732E-09 |
| Normal-vs-Female |
2.03139999999102E-05 |
| Male-vs-Female |
2.274300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.93240000000628E-05 |
| Normal-vs-Age(41-60Yrs) |
1.84263999999379E-05 |
| Normal-vs-Age(61-80Yrs) |
2.92169999971392E-07 |
| Normal-vs-Age(81-100Yrs) |
1.633650E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.884600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.858000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.606000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.639600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.525400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.546800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.924800E-01 |
| Classical-VS-Follicular |
6.479800E-02 |
| Classical-VS-Other |
1.108050E-01 |
| Classical-VS-Normal |
2.20489999999129E-05 |
| Tall-VS-Follicular |
6.853600E-01 |
| Tall-VS-Other |
2.644600E-01 |
| Tall-VS-Normal |
1.754120E-04 |
| Follicular-VS-Other |
5.316000E-01 |
| Follicular-VS-Normal |
3.07300000002009E-06 |
| Other-VS-Normal |
1.875360E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.91829999995896E-07 |
| Normal-vs-N1 |
7.55460000001484E-07 |
| N0-vs-N1 |
3.327600E-01 |
|
|
